KRAS and neoplasm: In conclusion, our work uncovers the phospholipid transporter PITPNC1 as a KRAS effector that controls central transcriptional and signalling nodes (i.e. MYC and mTOR) and unveils novel therapeutic strategies for KRAS-driven tumours in the context of a PITPNC1-regulated transcriptional network.